Episode 11. ASH22 Recap: Lymphoma and CLL
Blood Cancer Talks
00:00
The Importance of K-67 Scores in the ASCT Trial
The 80% crossover to Abrutinib in the ASCT and the fact that they added Rituximab maintenance midway through the trial when that became approved both stood out to me as good examples of how to do a trial well. From my reading of the slides it looked like only 26% of patients had high K-67 scores which I know is just one marker of the kind of aggressiveness of mental problem coma. Well I have a lot more questions to ask here we didn't even get a chance to talk about a few slides BSL lymphoma although if you like D-LBC you'll probably have its time in the summer last Ash so it won't be
Transcript
Play full episode
